Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Abbisko Cayman (2256 HK): Licensing Holds 2025, Pimicotinib To Carry 2026, Irpagratinib Future Draw

Abbisko Cayman (2256 HK): Pimicotinib Approval A Big Positive, Pipeline Offers Promise

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/abbisko-cayman-limited" target="_blank" data-smartkarma-citation="entities:33511:1" rel="noopener">Abbisko Cayman (2256 HK)</a> is placing 42.9M shares at the price of HK$12.18 per share to raise HK$517M. Placing shares represent ~6.4% of the total number of issued shares.</li>
<li>The placing price indicates a discount of 8.4% to the undisturbed closing price. The placement is expected to take place on April 28, 2026.  </li>
<li>Abbisko intends to use the net proceeds for the R&amp;D of innovative oncology and non-oncology drug candidates, advancement of international clinical trials, and potential commercialization activities.</li>
</ul>



Abbisko Cayman (2256 HK) is placing 42.9M shares at the price of HK$12.18 per share to raise HK$517M. Placing shares represent ~6.4% of the total number of issued shares.
The placing price indicates a discount of 8.4% to the undisturbed closing price. The placement is expected to take place on April 28, 2026.  
Abbisko intends to use the net proceeds for the R&amp;D of innovative oncology and non-oncology drug candidates, advancement of international clinical trials, and potential commercialization activities.


Sichuan Kelun-Biotech Biopharmaceutical (6990 HK)

Abbisko Cayman (2256 HK): Placement of Shares to Feed R&D Pipeline